Pharmaceutical compositions for the treatment of hydropic conditions
    1.
    发明授权
    Pharmaceutical compositions for the treatment of hydropic conditions 失效
    用于治疗嗜酸性病症的药物组合物

    公开(公告)号:US3963834A

    公开(公告)日:1976-06-15

    申请号:US569635

    申请日:1975-04-18

    IPC分类号: A61K31/565 A61K31/56

    CPC分类号: A61K31/565

    摘要: Pharmaceutical compositions comprisingA. at least one member of the group consiting of 5-(4-chloro-5-sulfamoyl-2-thenylaminophenyl)-tetrazole and the pharmacologically compatible salts thereofB. at least one member of the group consisting of 3-(3-oxo-17.beta.-hydroxy-4,6-androstadien-17.alpha.-yl)-propionic acid-.gamma.-lactone and the pharmacologically compatible salts of 3-(3-oxo-17.beta.-hydoxy-4,6-androstadien-17.alpha.-yl)-propionic acid, and a pharmaceutical carrier;Possess outstanding activity for treating hydropic conditions and prevent undesirable increased excretion of potassium without at the same time impairing the desired excretion of water and sodium.

    摘要翻译: 包含A的药物组合物。5-(4-氯-4-磺酰基-2-苯基苯胺基) - 特他唑组的至少一个组成成员及其药理学兼容性的B。至少一个组成成员, (3-OXO-17β-羟基-4-4,6-ANDROSTADIEN-17α-YL)-PROPIONIC ACID-γ-LACTONE和3-(3-氧代-17β-羟基-4- ANDROSTADIEN-17α-YL) - 丙酸和药物载体; 处理水文条件的不可忽视的活动,并且防止不可预期地提高钾的排放量,同时不影响所需的水和钠的排放。

    Pharmaceutical composition and method for the treatment of hydropic
conditions
    2.
    发明授权
    Pharmaceutical composition and method for the treatment of hydropic conditions 失效
    用于治疗嗜酸性病症的药物组合物和方法

    公开(公告)号:US4031213A

    公开(公告)日:1977-06-21

    申请号:US568640

    申请日:1975-04-16

    IPC分类号: A61K31/565 A61L13/00

    CPC分类号: A61K31/565

    摘要: Pharmaceutical compositions comprisingA. at least one member of 5-(4-chloro-5-sulfamoyl-2-thenylaminophenyl)-tetrazole and the pharmacologically compatible salts thereof,B. 3-(3-oxo-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)-propionic acid-.gamma.-lactone, andC. a pharmaceutical diluent or carrierPossess outstanding activity for treating hydropic conditions and prevent undesirable increased excretion of potassium without at the same time impairing the desired excretion of water and sodium.

    摘要翻译: 包含A.至少一个5-(4-氯-4-磺酰基-2-噻吩-2-基)苯并噻唑的一个成员的药物组合物及其药理学兼容的盐,B. 3-(3-氧代-7α-乙酰基-17β -HYDROXY-4-ANDROSTEN-17α-YL)-PROPIONIC ACID-γ-LACTONE,以及C.一种药物稀释剂或载体,用于治疗水解条件的不可忽视的活性,并且预防不可预期地增加不同时间的硫酸铵,同时不影响预期 水和钠的清除。

    3-Alkyl-4-sulfamoyl-aniline therapeutic compositions
    3.
    发明授权
    3-Alkyl-4-sulfamoyl-aniline therapeutic compositions 失效
    3-烷基-4-氨磺酰基 - 苯胺治疗组合物

    公开(公告)号:US3991188A

    公开(公告)日:1976-11-09

    申请号:US593089

    申请日:1975-07-03

    IPC分类号: A61K31/63 A61K31/625

    CPC分类号: A61K31/63 Y10S514/869

    摘要: New 3-alkyl-4-sulfamoyl-aniline compounds of the formula ##SPC1##WhereinR.sub.1 is phenyl, furyl or thienyl;R.sub.2 is carboxyl or tetrazolyl-(5)R.sub.4 is a straight-chain or branched alkyl radical of from 2 to 5 carbon atoms; andn is 1 or 2;And the pharmacologically compatible salts thereof; are outstandingly effective saluretic compounds, particularly when administered enterally.

    摘要翻译: 式WHEREIN R1的新的3-烷基-4-氨磺酰基 - 苯胺化合物是苯基,呋喃基或噻吩基; R2是羧基或四唑基 - (5)R4是2至5个碳原子的直链或支链烷基; 和N IS 1 OR 2; 及其药理学兼容性; 具有非常有效的挥发性化合物,特别是在进行管理时尤其如此。